Needham & Company LLC Initiates Coverage on Hinge Health (NYSE:HNGE)

Analysts at Needham & Company LLC started coverage on shares of Hinge Health (NYSE:HNGE - Get Free Report) in a research report issued on Monday,Benzinga reports. The firm set a "buy" rating and a $47.00 price target on the stock. Needham & Company LLC's price target points to a potential upside of 35.21% from the company's previous close.

HNGE has been the subject of a number of other reports. Wall Street Zen upgraded Hinge Health to a "hold" rating in a research note on Monday, June 2nd. KeyCorp started coverage on Hinge Health in a research report on Monday. They set an "overweight" rating and a $45.00 price objective for the company. Canaccord Genuity Group initiated coverage on Hinge Health in a research note on Monday. They issued a "buy" rating and a $52.00 target price on the stock. Finally, Barclays started coverage on shares of Hinge Health in a research report on Monday. They set an "overweight" rating and a $43.00 price target for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $46.75.

Hinge Health Stock Down 0.7%

Shares of NYSE HNGE opened at $34.76 on Monday. Hinge Health has a twelve month low of $33.42 and a twelve month high of $43.80.

Hinge Health Company Profile

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.